Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.

Slides:

Advertisements

Similar presentations

“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,

Advertisements

Cognitive, neurological and adaptive behaviour functioning among children with perinatally-acquired HIV infection Anita Shet, Smitha Holla, Vijaya Raman,

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.

Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,

High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.

HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)

ACTG 333 The Antiviral Effect of Switching from Saquinavir to the New Formulation of Saquinavir vs. Switching to Indinavir After >1 year of Saquinavir.

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,

DNA methylation as an epigenetic marker in HIV-2 disease in West Africa? Alberta Davis MRC Laboratories, Gambia 18th January 2013.

Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.

Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha,

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Management and Development for Health (MDH)

The Interplay of the Osteoprotegerin/RANKL Axis and Dysfunctional HDL in HIV-Infected Adults AIDS Clinical Trials Group Study NWCS 332/A5078 Kelesidis.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.

HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.

Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.

T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April

Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.

Introductory talk D Costagliola.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

Epidemiology of non-B clade forms of HIV-1 in MSM in the UK Fox J 1, Duda A 2,Green H 3, Dunn D 3, Kaye S 1, McClure M 1, Fidler S 1 Division of Medicine,

A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.

What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.

Poor linkage to care despite significant improvement in access to early cART – data from Test and Keep in Care (TAK) project. Leah Shepherd, Magdalena.

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Viral tropism by geno2pheno as.

Evolution of the Functional Profile of HIV-Specific CD8+ T cells in a Cohort of Long Term Nonprogressors M López, N Rallón, A Peris, M Salgado, B Rodés,

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.

Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

Impact of immune-driven sequence variation in HIV- 1 subtype C Gag-protease on viral fitness and clinical outcome Thumbi Ndung’u, BVM, PhD HIV Pathogenesis.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

IAS 2014, Melbourne Mechanisms of non-pathogenicity in HIV- Lessons from paediatric infection.

Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.

HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,

SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.

1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.

Deferred antiretroviral therapy is associated with lower eGFR in HIV- positive individuals with high CD4 counts A Mocroft 1, AC Achhra 2, M Ross 3, L Ryom.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,

G. E. Martin. , N. Pantazis. , M. Hoffmann. , S. Hickling, J. Hurst, J

Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.

Higher HDL, better brain

Catherine K. Koofhethile 21st IAS July,2016 Durban, SA

Accounting for uncertainty in the timing of seroconversion in combined models for pre- and post-treatment CD4 counts in HIV-patients Oliver Stirrup, Andrew.

Quantifying the Impact of HIV Escape from CTL

Chronic Kidney Disease in HIV Infection: An Urban Epidemic

Figure 2 Systemic immune responses to cryptococcal antigen

Follicular CD8+ T-cells (fCD8) in GALT are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during PHI John Thornhill Imperial.

Management and Development for Health (MDH)

Biomarkers as Endpoints

Presentation transcript:

Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker 3, Rodney Phillips 2, John Frater 2, Myra McClure 1, Sarah Fidler 1 and the SPARTAC Trial Investigators 1 Imperial College London, 2 Oxford University, 3 MRC Clinical Trials Unit

Background Immune activation is an independent predictor of HIV-1 disease progression 1 High CD38 expression on CD4 and CD8 cells associated with worse outcome Raised inflammatory and coagulation biomarkers IL-6 and D- dimer in chronic HIV infection predictive of adverse outcome 2 1 Hazenburg et al. AIDS Sep 5;17(13): Kuller et al PLoS Med Oct 21;5(10):e203.

Carriers of class 1 alleles HLA-B*27 and B*57 have delayed HIV progression. Carrington & O Brien. Annu. Rev. Med :535–51

Hypothesis & Aims Hypothesis: Individuals with protective HLA types have low levels of immune activation and inflammatory biomarkers, contributing to reduced disease progression Aims: To examine the relationship between protective HLA types and markers of immune activation, inflammation and coagulation in individuals with Primary HIV infection

Methods Participants enrolled in the SPARTAC trial: a RCT of ART intervention versus no therapy in Primary HIV infection (PHI) Cross sectional analysis of UK participants at seroconversion (n=148) PBMCs analysed by flow cytometry for CD38 expression on CD8 and CD4 T-cells. IL-6 and D-dimer measured from stored plasma. HLA type determined by sequence specific PCR. Patients categorised as HLA B*57, HLA B*27, or other HLA type Relationship between HLA type, immune activation, plasma HIV-RNA, and other baseline factors examined using linear regression

Baseline Characteristics (n=148) Baseline variableNumber or Median(%) or [IQR] Sex:Male142(96) Female6(4) Risk group:MSM138(93) Heterosexual9(6) Other / unknown1(1) Age (years)34.5[29,41] Estimated time from infection (days)73[47,93] Clade B133(90) CD4 (cells/mm 3 )540[405, 673] HIV-RNA (copies/ml)58835[11827, ]

Results Variable Number or Median (%) or [IQR] HLA B*57 +ve10/145(7) HLA B*27 +ve14/145(10) CD8 CD38 expression (%)40[25.4, 60] CD4 CD38 expression (%)52[38, 75] IL-6 (pg/ml)1.5[0.9, 2.7] D-dimer (μg/ml)0.38[0.23, 0.6] IL-6 and D-dimer correlated with each other (p=0.004) and CD8 CD38% expression (p=0.03 for IL-6, p=0.005 for d dimer). CD4 CD38 expression correlated with CD8 CD38 expression (p<0.0001)

CD8 activation and HLA B*57 CD4 activation and HLA B*57 Mean activation 46% vs. 15% p< Relative difference of 31% Mean activation 53% vs. 36% p=0.005 Relative difference of 17%

Factors associated with immune activation in Primary HIV infection Univariate Multivariate* Parameter p-value95% CI p-value95% CI CD8 CD38 % Age (+10 years) 0.8-3, 4.7 CD4 (+100 cells) , -0.5 HIV-RNA (+1og) < , 14< , 12 HLA B*57 < , -18< , -10 HLA B* , 5.2 BMI (+1 kg/m 2 ) 0.4-2, 0.6 BP >140/ , 11 CD4 CD38 % Age (+10 years) , , CD4(+100 cells) , , 0. 1 HIV-RNA (+1og) 0.4-2, 4.7 HLA B* , , -2 HLA B* , 12 BMI (+1 kg/m 2 ) , 0.5 BP > 140/ , , 33 * variable carried through to multivariate analysis if p<0.1 in univariate model

D dimer and HLA B*27 status Geometric mean D-dimer 0.40 vs.0.24 μ g/ml p=0.003 Relative difference of 40% (95% CI 15%, 58%).

Factors associated with D dimer in Primary HIV infection Univariate Multivariate Parameter p-value95% CI p-value95% CI D dimer Age (+10 years) , , 0.1 CD4 (+100 cells) , HIV-RNA (+1log) < , 0.2< , 0.1 HLA B* , 0.1 HLA B* , ,-0.03 BMI (+1 kg/m 2 ) , 0.02 BP>140/ , 0.1

Discussion Protective HLA types associated with lower immune activation and fibrinolysis This effect is independent of plasma HIV-RNA. T cell activation also associated with increased viral load, age and hypertension Future analysis to develop algorithm for predicting disease progression at time of Primary HIV diagnosis

Conclusion HLA B*57 positive individuals had lower levels of both CD8 and CD4 immune activation in Primary HIV Infection. HLA B*27 positive individuals had lower D-dimer levels HLA associated limitation of immune activation and/or fibrinolysis may additively contribute towards delayed HIV progression in individuals with protective HLA types.

Acknowledgments SPARTAC trial participants MRC CTU – Abdel Babiker – Kholoud Porter – Katherine Boyd Imperial College – Sarah Fidler – Myra McClure Oxford University – Stephen Hickling – Rodney Phillips – John Frater St Mary’s Hospital – Kevin Marriott NIHR BRC